Skip to content

Asset turnover at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
0.3×-0.1×
ALN
Alnylam PharmaceuticalsALNY
0.9×+0.3×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-0.1×
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
+0.9×
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
0.1×0.0×
Maravai LifeSciences Holdings, Inc. logo
Maravai LifeSciences Holdings, Inc.MRVI
0.2×0.0×

Other financials

Income statement

See full
Revenue$8.2M-12.8%
Operating income-$11.4M-14.4%
Net income-$9.1M-3.0%
EPS (diluted)-$0.54+53.8%

Balance sheet

See full
Cash & equivalents$31.1M+32.9%
Total debt$2.5M-17.5%
Total equity$198.6M+632%
Total assets$235.5M+138%

Cash flow

See full
Operating cash flow-$22.1M+5.7%
CapEx$19.0K
Free cash flow-$22.1M+5.6%

Valuation

See full
Market cap$480.77M+262%
Enterprise value$452.14M+302%
P/S6.8×+2.6×

Profitability

See full
Operating margin-116.8%-26.1pp
Net margin-103.6%-22.7pp
FCF margin-150%-231pp

Returns & leverage

See full
Return on equity-36.9%-15.1pp
Debt / equity-0.1×
Current ratio6.6×+4.6×

Where this comes from

Calculated from Assembly Biosciences’s reported figures.

Based on trailing twelve months.

The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Assembly Biosciences's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Assembly Biosciences's asset turnover?
Assembly Biosciences (ASMB) reported asset turnover of 0.4× in Q1 2026.
How has Assembly Biosciences's asset turnover changed year-over-year?
Assembly Biosciences's asset turnover increased by 44.7% year-over-year, from 0.3× to 0.4×.
What is the long-term trend for Assembly Biosciences's asset turnover?
Over 4 years (2020 to 2025), Assembly Biosciences's asset turnover has grown at a 10.9% compound annual growth rate (CAGR), from 0.3× to 0.4×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.